Julie R Park, MD

Professional History

Board Certified:

Pediatric Hematology-Oncology

Medical/Professional School:

University of Vermont College of Medicine, Burlington

Clinical Interests:

Neuroblastoma, Novel therapies, Supportive care guidelines for care of oncologic patients, Post-transplant lymphoproliferative disease

Description of Research:

I am an active member of the Children's Oncology Group (COG) Consortium, coordinating the center's participation in clinical trials for treatment of neuroblastoma and non-Hodgkin lymphoma. As the oncology division director of Advanced Developmental Therapeutics, I oversee participation in national NIH-funded Phase I clinical research consortia, including the COG Phase I Consortium and the New Approaches to Neuroblastoma Therapy (NANT) Consortium.

My primary research focus is to discover novel therapies for the treatment of high-risk pediatric neuroblastoma using both adoptive immunotherapy and novel molecularly targeted approaches. I am the principal investigator for a national randomized Phase III trial within COG for treatment of newly diagnosed high-risk neuroblastoma.

Key Publications:

Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. Apr 2007;15(4):825?833.

Honors & Awards:

Seattle Metropolitan Magazine Top Doctor, 2006, 2008

Seattle Magazine Top Doc, 2008

2007: NIH Career Development Award (K Award) Winner